MSLN and pancreatic neoplasm: The hypomethylation of the promoter was noted in mesothelin-expressing pancreatic cancer specimens, and the treatment of a non-expressing pancreatic cancer cell line with demethylating agents could induce the expression of mesothelin, suggesting that epigenetic mechanisms regulate mesothelin expression in this cell type [54].